ESLA Q3 2023 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$2M

Net Income

-$2M

EPS (Diluted)

$-1.78

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$275,192

Free Cash Flow

-$275,192

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$27M

Total Liabilities

$17M

Stockholders' Equity

$10M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$2M	-$549,180	-240.6%
Net Income	-$2M	-$344,863	-442.4%